scPharmaceuticals Inc. (SCPH)

US — Healthcare Sector
Peers: MIST  ONCY  MCRB  LIFE  DMAC  LYRA  CNTA    SCPS  MNPR  KTTA  IOVA 

Automate Your Wheel Strategy on SCPH

With Tiblio's Option Bot, you can configure your own wheel strategy including SCPH - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol SCPH
  • Rev/Share 0.7821
  • Book/Share -0.0955
  • PB -38.1084
  • Debt/Equity -10.212
  • CurrentRatio 5.4777
  • ROIC -0.8901

 

  • MktCap 192162880.0
  • FreeCF/Share -1.3041
  • PFCF -2.7453
  • PE -2.1522
  • Debt/Assets 0.5756
  • DivYield 0
  • ROE -7.5413

 

  • Rating B-
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 5
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

scPharmaceuticals: Furoscix Sales To Accelerate Throughout 2025
SCPH
Published: May 22, 2025 by: Seeking Alpha
Sentiment: Neutral

Shares of scPharmaceuticals have lost 37% over the past 3 years and are down 11% in 2025. Furoscix's subcutaneous administration offers the potential to keep heart failure patients at home longer and cut down on hospital readmissions. Q1 seasonality is in the rearview mirror, with multiple tailwinds, including Medicare redesign and label expansion, to fuel growth going forward.

Read More
image for news scPharmaceuticals: Furoscix Sales To Accelerate Throughout 2025
scPharmaceuticals Inc. (SCPH) Q4 2024 Earnings Call Transcript
SCPH
Published: March 19, 2025 by: Seeking Alpha
Sentiment: Neutral

scPharmaceuticals Inc. (NASDAQ:SCPH ) Q4 2024 Results Conference Call March 19, 2025 4:30 PM ET Company Participants Nick Colangelo - Investor Relations John Tucker - Chief Executive Officer Steve Parsons - Senior Vice President of Commercial Rachael Nokes - Chief Financial Officer Conference Call Participants Stacy Ku - TD Cowen Glen Santangelo - Jefferies Roanna Ruiz - Leerink Partners Douglas Tsao - H.C. Wainwright Naz Rahman - Maxim Group Chase Knickerbocker - Craig-Hallum Operator Good afternoon, and welcome to scPharmaceuticals Fourth Quarter and Full Year 2024 Earnings Conference Call.

Read More
image for news scPharmaceuticals Inc. (SCPH) Q4 2024 Earnings Call Transcript
ScPharmaceuticals, Inc. (SCPH) Expected to Beat Earnings Estimates: Should You Buy?
SCPH
Published: March 05, 2025 by: Zacks Investment Research
Sentiment: Positive

ScPharmaceuticals (SCPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Read More
image for news ScPharmaceuticals, Inc. (SCPH) Expected to Beat Earnings Estimates: Should You Buy?
scPharmaceuticals Announces Participation in Two Upcoming Investor Conferences
SCPH
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral

BURLINGTON, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that John Tucker, President and Chief Executive Officer, will present at the following upcoming investor conferences:

Read More
image for news scPharmaceuticals Announces Participation in Two Upcoming Investor Conferences

About scPharmaceuticals Inc. (SCPH)

  • IPO Date 2017-11-17
  • Website https://www.scpharmaceuticals.com
  • Industry Biotechnology
  • CEO Mr. John H. Tucker
  • Employees 162

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. scPharmaceuticals Inc. was incorporated in 2013 and is headquartered in Burlington, Massachusetts.